{"id":"saquinavir-ritonavir","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"10-15","effect":"Lipid abnormalities"},{"rate":"2-5","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saquinavir is an HIV protease inhibitor that binds to the active site of HIV protease and prevents the maturation of viral particles. Ritonavir is a potent protease inhibitor used as a pharmacokinetic booster that inhibits cytochrome P450 metabolism, significantly increasing saquinavir plasma concentrations and bioavailability. Together, they provide enhanced antiviral activity against HIV-1.","oneSentence":"Saquinavir and ritonavir are protease inhibitors that block HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:57.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients"},{"name":"HIV-1 infection in antiretroviral-naive patients"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00056641","phase":"PHASE2","title":"Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02-18","conditions":"HIV Infections","enrollment":328},{"nctId":"NCT00003008","phase":"PHASE2","title":"Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-12-15","conditions":"Sarcoma","enrollment":33},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00000891","phase":"PHASE2","title":"Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00000892","phase":"NA","title":"A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00000906","phase":"PHASE1","title":"Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00051831","phase":"NA","title":"Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-10","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00001108","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00102206","phase":"PHASE2","title":"A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00005762","phase":"NA","title":"Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-03","conditions":"HIV Infections","enrollment":90},{"nctId":"NCT00084058","phase":"PHASE1, PHASE2","title":"Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT00001133","phase":"PHASE1","title":"Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00000898","phase":"NA","title":"The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT00000920","phase":"PHASE1","title":"Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Pregnancy","enrollment":24},{"nctId":"NCT00000914","phase":"NA","title":"A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT00000913","phase":"PHASE2","title":"A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00000941","phase":"PHASE1","title":"A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT00145561","phase":"PHASE1, PHASE2","title":"The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-infected Pregnant Women.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2005-08","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT00379405","phase":"PHASE4","title":"Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2006-06","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00435929","phase":"PHASE1","title":"A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT00100984","phase":"PHASE4","title":"A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2004-07-21","conditions":"HIV Infection","enrollment":8},{"nctId":"NCT01638650","phase":"PHASE1","title":"A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-01","conditions":"HIV Infections","enrollment":23},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00623597","phase":"PHASE2","title":"A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT00665847","phase":"PHASE2","title":"TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-11","conditions":"HIV-1","enrollment":103},{"nctId":"NCT00476983","phase":"PHASE2, PHASE3","title":"Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg","status":"WITHDRAWN","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"","conditions":"Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID","enrollment":""},{"nctId":"NCT00476359","phase":"PHASE4","title":"A PK and Salvage Study for Children With HIV-infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-10","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00622141","phase":"PHASE1, PHASE2","title":"Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®","status":"WITHDRAWN","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT02239835","phase":"PHASE2","title":"Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"1999-12","conditions":"HIV Infections","enrollment":79},{"nctId":"NCT02023450","phase":"EARLY_PHASE1","title":"Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2013-12","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00622206","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Low Dose Ritonavir","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-01","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00476502","phase":"","title":"Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2006-02","conditions":"HIV Infections","enrollment":250},{"nctId":"NCT00400738","phase":"PHASE2","title":"The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2004-03","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT00122603","phase":"PHASE2","title":"Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2005-12","conditions":"HIV Infections","enrollment":61},{"nctId":"NCT00105079","phase":"PHASE3","title":"GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-04","conditions":"HIV Infections","enrollment":337},{"nctId":"NCT00438152","phase":"PHASE4","title":"Lopinavir Capsules to Kaletra or Invirase Tablets","status":"COMPLETED","sponsor":"Royal Free Hampstead NHS Trust","startDate":"2006-09","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00004584","phase":"PHASE2","title":"Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-12","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00046033","phase":"PHASE2","title":"Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT00035932","phase":"PHASE3","title":"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-11","conditions":"HIV Infections","enrollment":571},{"nctId":"NCT00717067","phase":"PHASE4","title":"Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2008-07","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":30},{"nctId":"NCT00389402","phase":"PHASE4","title":"BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes","status":"COMPLETED","sponsor":"International Antiviral Therapy Evaluation Center","startDate":"2006-07","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00192608","phase":"NA","title":"A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-11","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00038532","phase":"PHASE2","title":"Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART","status":"COMPLETED","sponsor":"Abbott","startDate":"2001-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00043953","phase":"PHASE2","title":"Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-08","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00038519","phase":"PHASE2, PHASE3","title":"Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor","status":"COMPLETED","sponsor":"Abbott","startDate":"2001-04","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT00285883","phase":"PHASE3","title":"Directly Observed Therapy in High Risk Populations in Newark, NJ","status":"COMPLETED","sponsor":"Saint Michael's Medical Center","startDate":"2004-04","conditions":"Directly Observed Therapy, HIV Infections","enrollment":30},{"nctId":"NCT00002378","phase":"PHASE3","title":"A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":825},{"nctId":"NCT00002178","phase":"PHASE3","title":"A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":375},{"nctId":"NCT00002448","phase":"PHASE3","title":"A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-10","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00002440","phase":"PHASE2","title":"A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00002374","phase":"PHASE3","title":"A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00002447","phase":"PHASE3","title":"A Study to Compare Two Anti-HIV Drug Combinations","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-10","conditions":"HIV Infections","enrollment":146}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"IMMUNE RECONSTITUTION SYNDROME"},{"count":2,"reaction":"LIPOATROPHY"},{"count":2,"reaction":"NEPHROLITHIASIS"},{"count":1,"reaction":"ACNE"},{"count":1,"reaction":"ANGINA PECTORIS"},{"count":1,"reaction":"BODY MASS INDEX DECREASED"},{"count":1,"reaction":"CARDIOMYOPATHY"},{"count":1,"reaction":"CENTRAL NERVOUS SYSTEM LESION"},{"count":1,"reaction":"CIRCULATORY COLLAPSE"},{"count":1,"reaction":"COMMUNICATION DISORDER"}],"_approvalHistory":[],"publicationCount":206,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Invirase/Norvir"],"phase":"marketed","status":"active","brandName":"saquinavir/ritonavir","genericName":"saquinavir/ritonavir","companyName":"International Antiviral Therapy Evaluation Center","companyId":"international-antiviral-therapy-evaluation-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saquinavir and ritonavir are protease inhibitors that block HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection in antiretroviral-naive patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}